Calcification-resistant biomaterials

• US 6,193,749 B1
• Filed: 09/17/1997
• Issued: 02/27/2001
• Est. Priority Date: 02/05/1996
• Status: Expired due to Term

• Current Assignee: St Jude Medical Incorporated (Abbott Laboratories Incorporated)
• Original Assignee: St Jude Medical Incorporated (Abbott Laboratories Incorporated)
• Inventors: Ogle, Matthew F., Schroeder, Richard F.
• Primary Examiner(s): Prebilic, Paul B.
• Application Number:
  US08/931,930
• Time in Patent Office: 1,259 Days
• Field of Search: 623/1, 623/2, 623/11, 623/901, 623/1.42, 623/1.46, 623/1.48, 623/2.42, 623/926, 8 9/411
• US Class Current: 623/1.42
• CPC Class Codes: A61L 2400/02 Treatment of implants to prevent calcification or mineralisation in vivo
• CPC Class Codes: A61L 27/36 containing ingredients of undetermined constitution or reaction products thereof , e.g. transplant tissue, natural bone, extracellular matrix isolated natural compounds, e.g. collagen A61L27/24
• CPC Class Codes: A61L 27/50 Materials characterised by their function or physical properties , e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
• CPC Class Codes: Y10S 623/926 Synthetic

Abstract

In general, the invention features a bioprosthetic article including a biocompatible material having at least one bound exogenous storage structure, the storage structure having a quantity of calcification inhibitors releasably bound thereto. The storage structure can be a protein or a synthetic polymer. The calcification inhibitors include metal ions and phosphatase inhibitors generally. Bifunctional metal chelators can be bound to endogenous proteins to deliver metal ions.

Claims

1. A bioprosthetic article comprising a biocompatible material and an exogenous storage structure that is bound to the biocompatible material, said storage structure comprising a metal binding protein and said storage structure having a quantity of calcification inhibitors releasably bound thereto.

2. The bioprosthetic article of claim 1, wherein said biocompatible material comprises natural tissue.

3. The bioprosthetic article of claim 2, wherein said natural tissue is selected from the group consisting of porcine heart valves, aortic roots, aortic walls, aortic leaflets, bovine pericardial tissues, connective tissues, dura matter, homograft tissue, bypass grafts, tendons, ligaments, skin patches, blood vessels, human umbilical tissue and bone.

4. The bioprosthetic article of claim 1, wherein said biocompatible material comprises a polymer.

5. The bioprosthetic article of claim 1, wherein said protein comprises ferritin.

6. The bioprosthetic article of claim 1, wherein said calcification inhibitor comprises a metal cation.

7. The bioprosthetic article of claim 6, wherein said metal cations are selected from the group consisting of Al⁺³, Fe⁺³, and Mg⁺².

8. The bioprosthetic article of claim 1, wherein said calcification inhibitor comprises a diphosphate.

9. The bioprosthetic article of claim 1, wherein said calcification inhibitor comprises a phosphatase inhibitor.

10. The bioprosthetic article of claim 9, wherein said phosphatase inhibitor is selected from the group consisting of phosphate ions, Ga⁺³, La⁺³, borate ions, oxalate ions, cyanide ions, L-phenylalanine, urea, Zn⁺², glycine, propylamine, lavamisole, and arsenate ions.

11. The bioprosthetic article of claim 1, wherein said binding of said storage structure to said biocompatible material is primarily covalent in character.

12. The bioprosthetic article of claim 1, wherein said binding of said storage structure to said biocompatible material is characterized by a plurality of non-covalent interactions.

13. The bioprosthetic article of claim 1, wherein said exogenous storage structure further comprises a targeting molecule.

14. A bioprosthetic article comprising a biocompatible material and an exogenous, attached protein with bound bifunctional chelators and with a quantity of multivalent metal cations releasably bound to the bifunctional chelators.

18. The bioprosthetic article of claim 14 wherein the multivalent metal cations comprise ions selected from the group consisting of Al⁺³, Fe⁺³, and Mg⁺².

19. The bioprosthetic article of claim 14 wherein the multivalent cations comprise Al⁺³.

20. The bioprosthetic article of claim 14 wherein the bifunctional chelator is selected from the group consisting of polyaminocarboxylate, polyaminophosphonate, bromoacetamide, maleimide, inidoester, thiophthalimide, N-hydroxysuccinimyl ester, pyridyl disulfide, phynyl azide, 0-acylisourea, diazonium hydrazine, carbonyl hydrazine, amino hydrazine, acyl hydrazine, diazonium semicarbazide, carbonyl semicarbazide, amino carbazide, acyl semicarbazide, thio semicarbazide, and cyclic polyaminocarboxylates and cyclic polyaminophosphonates having 12 to 16 atom rings.

15. A bioprosthetic article comprising a biocompatible material and an exogenous metal binding protein that is bound to the biocompatible material, said protein having a quantity of calcification inhibitors bound thereto, wherein said protein has been modified to create metal binding capability.

16. The bioprosthetic article of claim 15, wherein said protein is a synthetic protein.

17. A bioprosthetic article comprising a biocompatible material and an exogenous, macromolecular storage structure that is bound to the biocompatible material, said storage structure having a quantity of calcification inhibiting multivalent metal cations releasably bound thereto, wherein the storage structure comprises a synthetic organometallic polymer.